These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 29485740

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
    Nakai T, Saigusa D, Kato K, Fukuuchi T, Koshiba S, Yamamoto M, Suzuki N.
    Life Sci; 2024 Jun 01; 346():122641. PubMed ID: 38614299
    [Abstract] [Full Text] [Related]

  • 5. Use of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease-associated anemia in cats.
    Charles S, Süssenberger R, Settje T, Langston C, Lainesse C.
    J Vet Intern Med; 2024 Jun 01; 38(1):197-204. PubMed ID: 37740521
    [Abstract] [Full Text] [Related]

  • 6. Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice.
    Li L, Nakano D, Zhang A, Kittikulsuth W, Morisawa N, Ohsaki H, Suzuki N, Yamamoto M, Nishiyama A.
    J Pharmacol Sci; 2020 Dec 01; 144(4):229-236. PubMed ID: 33070842
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model.
    Noonan ML, Ni P, Agoro R, Sacks SA, Swallow EA, Wheeler JA, Clinkenbeard EL, Capitano ML, Prideaux M, Atkins GJ, Thompson WR, Allen MR, Broxmeyer HE, White KE.
    J Bone Miner Res; 2021 Jun 01; 36(6):1117-1130. PubMed ID: 33592127
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E, Cho KH, Harris ST, Flindt NR, Watt RK, Pai AB.
    Expert Opin Investig Drugs; 2020 Aug 01; 29(8):831-844. PubMed ID: 32476498
    [Abstract] [Full Text] [Related]

  • 18. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A.
    Eur J Pharmacol; 2021 Dec 05; 912():174583. PubMed ID: 34678238
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
    Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T.
    Am J Nephrol; 2021 Dec 05; 52(10-11):871-883. PubMed ID: 34569489
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.